The late-stage drug that hangs in the balance is PhaseBio's only one in clinical development. If it is transferred to SFJ Pharmaceuticals, PhaseBio would lose any share in its potential revenue until it returns at least 300% of SFJ's investment.
The late-stage drug that hangs in the balance is PhaseBio's only one in clinical development. If it is transferred to SFJ Pharmaceuticals, PhaseBio would lose any share in its potential revenue until it returns at least 300% of SFJ's investment.
